Are you missing out on thousands of pounds in lost pension income?

If you lose track of one of your pensions, you could be leaving yourself worse off in retirement

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

0.3880

-0.0320

(-7.62%)

At close: 04:00PM EST

0.3814

-0.01

(-1.70%)

After hours:

07:56PM EST

Trade prices are not sourced from all markets

Press releases

PR Newswire
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).
PR Newswire
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).
PR Newswire
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it has selected of Fortrea (FTRE) as the Company's Contract Research Organization (CRO) for global trials, including ACHIEVE and ACHIEVE2.